Welcome to our dedicated page for Chinook Therapeutics news (Ticker: KDNY), a resource for investors and traders seeking the latest updates and insights on Chinook Therapeutics stock.
Chinook Therapeutics, Inc. (NASDAQ: KDNY) delivers innovative therapies for kidney diseases through its precision medicine pipeline. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives shaping the future of nephrology care.
Access real-time information about phase 3 trials for atrasentan in IgA nephropathy, progress updates on zigakibart's BEYOND study, and early-stage developments of CHK-336 for hyperoxalurias. Our curated news collection includes FDA communications, partnership announcements, and peer-reviewed research findings directly impacting therapeutic advancements.
Stay informed about key events through verified press releases and objective analysis of trial data. Content is organized to highlight material developments in proteinuria reduction therapies, kidney function preservation strategies, and novel treatment mechanisms validated by single-cell RNA sequencing insights.
Bookmark this page for streamlined access to Chinook's latest scientific achievements and corporate updates. Regular monitoring ensures you never miss critical information about one of biotech's most focused kidney disease innovators.
Chinook Therapeutics (Nasdaq: KDNY) has paused dosing in the phase 1 clinical trial of CHK-336 after a serious adverse event (SAE) occurred in a participant. The event was reported as a Suspected Unexpected Severe Adverse Reaction (SUSAR) to the FDA. Initial findings suggest the SAE may be linked to a hypersensitivity reaction to the drug or its components. Dosing was halted immediately per protocol, and a thorough investigation is underway with expert consultants.
CHK-336 had previously shown good tolerance in 62 subjects at dosages up to 500 mg and multiple doses up to 60 mg daily for 14 days. The trial's next steps will be determined after a review by the Safety Monitoring Committee.
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced the approval of inducement grants for new employees, including stock options for 85,500 shares and restricted stock units for 44,580 shares, with an exercise price of $23.15, equivalent to the closing price on March 31, 2023. These grants are part of the 2022 Equity Inducement Plan and serve as a significant incentive for 16 new hires. The stock options will vest over four years and are subject to employment conditions, while the restricted stock units will vest annually over three years. This move aligns with Nasdaq listing Rule 5635(c)(4) and reflects Chinook's commitment to attract talent as it develops precision medicines for kidney diseases, including lead candidates in various clinical trials.
Chinook Therapeutics, a biopharmaceutical company focused on kidney disease treatments, will participate in the Guggenheim Healthcare Talks on April 4, 2023, at 10:45 am ET. This event includes a virtual fireside chat and 1x1 meetings with investors. Interested parties can access the live webcast and archived recordings through the company's website for 90 days. Chinook's lead program is atrasentan, currently in phase 3 trials for IgA nephropathy. Other candidates include BION-1301 and CHK-336, targeting rare kidney disorders. The company aims to leverage genetic insights to advance precision medicine for chronic kidney diseases.
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced that it will present several abstracts at the ISN World Congress of Nephrology 2023 from March 30 to April 2 in Bangkok, Thailand. Key presentations include:
- Atrasentan - Phase 3 trial results for IgA Nephropathy (ALIGN Study) and interim results from the AFFINITY Study.
- BION-1301 - Interim results from a Phase 1/2 study focused on IgA Nephropathy.
These studies highlight Chinook's commitment to precision medicines in kidney diseases.
Chinook Therapeutics (Nasdaq: KDNY) announced its participation in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 3:20 pm ET. The management will also engage in one-on-one meetings during the event. Investors can access the live webcast and an archived recording on the Investors section of Chinook’s website, available for 90 days post-event.
Chinook Therapeutics focuses on developing precision medicines for kidney diseases, with notable programs like atrasentan for IgA nephropathy in phase 3, and BION-1301 in phase 1/2 trials.
Chinook Therapeutics (Nasdaq: KDNY) announced the approval of employment inducement grants totaling 202,290 stock options and 61,145 restricted stock units for nine new hires, including significant grants for Chief Commercial Officer Andrew Oxtoby. The options have an exercise price of $21.82, aligning with the closing stock price on February 28, 2023. Vesting occurs over four years for options and three years for restricted units, contingent on ongoing employment. This initiative aligns with Nasdaq Rule 5635(c)(4) and aims to attract top talent to advance Chinook's precision medicines targeting rare kidney diseases.
Chinook Therapeutics (Nasdaq: KDNY) announced its participation in the 5th Chronic Kidney Disease Drug Development Summit in Boston from March 7-9, 2023. The company will present on critical topics related to kidney disease treatment, including a panel discussion on regulatory needs for rare, diabetic, and hypertensive kidney diseases. Key speakers include Tom Frohlich, COO, and Andrew King, CSO, discussing clinical trial designs and biomarkers for rare diseases. The event will also address inclusion criteria in trials for optimal patient selection. For more details, visit the CKD Summit website.
Chinook Therapeutics (Nasdaq: KDNY) reported its financial results for Q4 and the full year ending December 31, 2022. The company saw a revenue drop to $0.5 million for Q4 and $6.1 million for the year, down from $51.2 million and $51.6 million in 2021, mainly due to prior non-cash revenue from licensing agreements. R&D expenses surged to $43.0 million for Q4 and $141.2 million for the full year. Net losses widened to $62.6 million or $0.90 per share in Q4 and $187.9 million or $2.92 per share for the year. The company highlighted advancements in its clinical pipeline, including delays in reporting interim data from its phase 3 trial of atrasentan.
Chinook Therapeutics, Inc. (Nasdaq: KDNY) has appointed Andrew Oxtoby as chief commercial officer, as announced on February 15, 2023. Andrew brings over 20 years of biopharmaceutical experience, having formerly served as president and CEO of Aimmune Therapeutics and holding key roles at Eli Lilly. His appointment is seen as critical as Chinook prepares for significant milestones in its atrasentan and BION-1301 programs, targeting rare kidney diseases. The company aims to leverage Andrew's expertise to enhance commercial capabilities and ultimately impact patients suffering from chronic kidney conditions.
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced management's participation in a virtual fireside chat on February 14, 2023, at the SVB Securities Global Biopharma Conference at 11:20 am ET. The event will also include 1x1 meetings. Interested parties can access the live webcast and archived recordings through the Investors section of its website. Chinook focuses on precision medicines for kidney diseases, with key products like atrasentan and BION-1301 currently in clinical trials.
FAQ
What is the market cap of Chinook Therapeutics (KDNY)?
